News - Eisai, Gastro-intestinals


Current filters:


Popular Filters

FDA approves Eisai's Aciphex Sprinkle for GERD in children; Inovelon OKed in Japan


Japanese drug major Eisai (TYO: 4523) says that the US Food and Drug Administration has approved Aciphex…

AciphexAsia-PacificEisaiGastro-intestinalsInovelonNeurologicalNorth AmericaPharmaceuticalRegulation

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA


The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Regulatory briefs: Allergic reactions warning on Merck & Co’s Saphris; Eisai drops Pariet ER development


The US Food and Drug Administration is warning that serious allergic reactions have been reported with…

EisaiGastro-intestinalsMerck & CoNeurologicalNorth AmericaParietPharmaceuticalRegulationSaphris

Abbott and Eisai launch of PDER drug Lipacreon in Japan


Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary…

Abbott LaboratoriesAsia-PacificEisaiGastro-intestinalsLipacreonMarkets & MarketingPharmaceutical

Back to top